Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma

Emily Padfield, Hayley P Ellis, Kathreena M Kurian

Research output: Contribution to journalArticle (Academic Journal)peer-review

179 Citations (Scopus)
410 Downloads (Pure)


Epidermal growth factor receptor (EGFR) and EGFRvIII analysis is of current interest in glioblastoma - the most common malignant primary CNS tumor, because of new EGFRvIII vaccine trials underway. EGFR activation in glioblastoma promotes cellular proliferation via activation of MAPK and PI3K-Akt pathways, and EGFRvIII is the most common variant, leading to constitutively active EGFR. This review explains EGFR and EGFRvIII signaling in GBM; describes targeted therapy approaches to date including tyrosine kinase inhibitor, antibody-based therapies, vaccines and pre-clinical RNA-based therapies, and discusses the difficulties encountered with these approaches including pathway redundancy and intratumoral heterogeneity.

Original languageEnglish
Article number5
Number of pages8
JournalFrontiers in Oncology
Publication statusPublished - 29 Jan 2015


  • EGFR
  • EFGR inhibitors
  • glioblastoma multiforme
  • molecular marker


Dive into the research topics of 'Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma'. Together they form a unique fingerprint.

Cite this